Expertise in
1
conditions

Pilar G. Diz

Leon, CL, ES 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
Leon, CL, ES 

Overview

Pilar Diz practices practicing medicine in Leon, Spain.

Diz is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Severe Acute Respiratory Syndrome (SARS), and Orchiectomy.

They are actively involved in clinical research, co-authoring 15 peer reviewed articles and participating in 8 clinical trials.

Locations

Leon, CL, Spain
Other Locations
ICO Bellvitge, Hospitalet Llobregat
Barcelona, CT, Spain
Complejo Asistencial Universitario de León
Madrid, MD, Spain
Jaen, AN, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Thoracic Tumours Register
Thoracic Tumours Register
Enrollment Status: Recruiting
Publish Date: April 23, 2026
Nivolumab Plus Ipilimumab Plus Two Cycles of Platinum-based Chemotherapy as First Line Treatment for Stage IV/Recurrent Non-small Cell Lung Cancer (NSCLC) Patients With Synchronous Brain Metastases
Nivolumab Plus Ipilimumab Plus Two Cycles of Platinum-based Chemotherapy as First Line Treatment for Stage IV/Recurrent Non-small Cell Lung Cancer (NSCLC) Patients With Synchronous Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: May 05, 2026
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed
Study Phase: Phase 2
A Phase II Open-label Multicenter Exploratory Study to Assess Efficacy of Pembrolizumab Re-challenge as Second or Further Line in Patients With Advanced Non - Small Cell Lung Cancer
A Phase II Open-label Multicenter Exploratory Study to Assess Efficacy of Pembrolizumab Re-challenge as Second or Further Line in Patients With Advanced Non - Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: March 24, 2025
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
Retrospective, Observational Study On The Efficacy And Safety Of Lorlatinib In ALK or ROS1 Metastatic Non-Small Cell Lung Cancer Patients Treated Within The Compassionate Use Program In Spain
Retrospective, Observational Study On The Efficacy And Safety Of Lorlatinib In ALK or ROS1 Metastatic Non-Small Cell Lung Cancer Patients Treated Within The Compassionate Use Program In Spain
Enrollment Status: Completed
Publish Date: March 30, 2023
Intervention Type: Drug
Observational Study on the Effectiveness and Safety of Vaccination Anti-SARS-CoV2 in Patients With Lung Cancer
Observational Study on the Effectiveness and Safety of Vaccination Anti-SARS-CoV2 in Patients With Lung Cancer
Enrollment Status: Completed
Publish Date: July 29, 2022
Intervention Type: Drug
Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease
Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease
Enrollment Status: Completed
Publish Date: June 27, 2022
A Retrospective, Multicenter and Observational Study of Osimertinib Monotherapy Treatment in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive Who Have Received the Treatment Within the Special Use Medication Program in Spain
A Retrospective, Multicenter and Observational Study of Osimertinib Monotherapy Treatment in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive Who Have Received the Treatment Within the Special Use Medication Program in Spain
Enrollment Status: Completed
Publish Date: June 03, 2022
Intervention Type: Drug
T790M Mutation Testing in Blood by Different Methodologies_RING Project
T790M Mutation Testing in Blood by Different Methodologies_RING Project
Enrollment Status: Completed
Publish Date: April 08, 2020
Intervention Type: Drug
View 7 Less Clinical Trials

15 Total Publications

Immunogenicity of COVID-19 vaccines in lung cancer patients.
Immunogenicity of COVID-19 vaccines in lung cancer patients.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 21, 2023

Frequently Asked Questions about Pilar G. Diz

Is Pilar G. Diz a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Pilar G. Diz is classified as an Advanced expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Pilar G. Diz participate in research or clinical trials?

Yes. Pilar G. Diz has published 15 articles and abstracts on conditions like Lung Cancer. You can view a list of Pilar G. Diz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Diz's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile